• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic Preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic Preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Viewpoints

A drug development model for the diseases the world forgot

Eschewing profit, over the past 20 years researchers at the Drugs for Neglected Diseases initiative have developed a dozen drugs accessible to the world’s most forgotten patients.

Home > Viewpoints

A drug development model for the diseases the world forgot

Eschewing profit, over the past 20 years researchers at the Drugs for Neglected Diseases initiative have developed a dozen drugs accessible to the world’s most forgotten patients.

Mother and child in a hospital
24 Aug 2023
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

By Dr Monique Wasunna, Africa Ambassador, DNDi

First published in Africa Arguments on 24 August 2023

Monique Wasunna

Twenty years ago, I travelled to Gedaref State in eastern Sudan. What I witnessed there deeply moved me and strengthened my resolve to contribute to medical innovation and improve treatments for people affected by a deadly and neglected disease called visceral leishmaniasis (VL).

In remote areas I visited, families with members affected by VL found it extremely difficult to reach Kassab Hospital, the nearest facility where diagnosis and treatment were offered. This fatal parasitic disease is prevalent in eastern Africa and causes weight loss, spleen and liver enlargement, anaemia, and intense fatigue – and kills 95% of affected people if left untreated. With 50,000 to 90,000 new cases reported worldwide annually, eastern Africa remains the world’s most affected region.

Due to the inadequate number of healthcare workers at Kassab Hospital, even those who managed to get there suffered financial losses from having to take weeks off work to stay with their sick loved ones. Compounding the issue, the primary treatment for the disease at the time, sodium stibogluconate (SSG), was a highly toxic drug that required 30 days of injections.

I am happy to say that today, the situation has improved significantly. After several years of medical research in Sudan and other endemic countries, the treatment duration for VL has been reduced to 17 days. Furthermore, the results from our recent study demonstrated that a 14-day combination treatment was equally effective, eliminating one painful daily injection and the potential toxicity associated with SSG. The World Health Organization (WHO) is currently reviewing this data.

This incredible success was achieved through non-profit drug development.

Neglected tropical diseases, such as visceral leishmaniasis, primarily affect people in the world’s poorest regions. Unfortunately, commercially driven medical research tends to overlook these populations because they are believed to lack the financial means to constitute a lucrative market for the traditional pharmaceutical industry. Drug development today is primarily skewed to areas with the greatest commercial return rather than those with the greatest public health needs.

But the alternative model that my organization, the Drugs for Neglected Diseases Initiative (DNDi), and our partners have pioneered since 2003 focuses on areas of the greatest need rather than the greatest profit. This means that we prioritize the development of treatments for diseases that have a high impact on public health, even if they are not directly profitable for the companies that develop them.

As I witnessed the suffering of patients with leishmaniasis in Kassab and later in other countries, it became clear that there was a need to work together. Collaborating with stakeholders from Kenya, Sudan, Ethiopia, and Uganda, we formed the Leishmaniasis East Africa Platform (LEAP).

The objective of LEAP was to facilitate clinical testing and registration of new treatments for VL in eastern Africa and ensure sustainable access to these treatments. In Sudan, LEAP’s impact has been significant; it led to successful clinical trials to test new and better medicines with partners at research facilities in Kassab. Similar efforts have been carried out in Ethiopia, Kenya, and Uganda.

Thanks to these efforts, DNDi gave hope to thousands of patients by delivering two shorter, safer treatments for VL in eastern Africa in 2022, including a drug combination for people living with HIV and VL.

This success story is not an isolated case. Since its creation 20 years ago, my organization has successfully developed 12 new treatments for six deadly neglected diseases, showing concretely that a not-for-profit model of drug development can work to improve the lives of millions of patients.

With researchers from all over the world working in partnership to find new treatments, this model encourages collaboration rather than competition. If a new molecule shows promise, we determine if it can be developed and produced at low cost. We put it through clinical trials to demonstrate its safety and effectiveness, have it registered in endemic countries, and ultimately work with partners to make sure it’s accessible to those who need it.

Partners in the Global South, where many neglected diseases are endemic, play a significant role in shaping R&D priorities by providing input in the most pressing diseases – the areas where research is needed – and the interventions that are most likely to be effective.

Teaming up with partners ensures that the research process is more affordable and that the treatments we develop are accessible to everyone, regardless of their socioeconomic status.

A textbook example is our work in the Democratic Republic of Congo, Guinea, and Malawi to find better treatments for sleeping sickness, a deadly disease. Twenty years ago, the only treatment widely available for stage two of this disease was an arsenic derivative so toxic that it killed one in 20 patients. In 2018, DNDi and its partners delivered fexinidazole, the first simple, safe, oral treatment for the most common form of the disease. We are now finalising the development of acoziborole, an all-new, single-dose oral drug that has the potential to eliminate sleeping sickness as a public health threat – for good.

Thanks to our partners, the dedication and hard work of clinicians, doctors, and nurses, and the active involvement of communities, we have successfully conducted complex clinical trials to the highest standards in remote regions that are sometimes shaken by conflict – all that at a fraction of the cost of traditional pharmaceutical research.

Our not-for-profit drug development model encourages open science, including – whether positive or negative. We have also used our experience to advocate for policies and political commitments to ensure everyone can benefit from scientific progress.

This model has built the capacity of African scientists like me to spearhead the critical mission of finding innovative treatments for neglected diseases that disproportionately affect our region. And we are not the only ones: other non-profit medical research organizations are also delivering better treatments for the most neglected populations – such as people affected by tuberculosis – and demonstrating that alternative models of drug development work.

Twenty years after my initial visit to Gedaref State, the situation has improved significantly. Currently, DNDi is supporting two VL treatment centres in Doka and Um el Kheir, where patients affected by the disease can now access improved treatments.

Yet, there is still much work to be done: we need to develop 100% oral medicines to make treatment even simpler for patients. But based on our previous successes in non-profit medical research, I’m confident that we can deliver them.

Photo credit: Paul Kamau-DNDi

Partnership Strengthening Capacities Sleeping sickness Visceral leishmaniasis Africa

Read, watch, share

Loading...
Centre of Excellence in India
News
14 Sep 2023

DNDi’s Centres of Excellence: Towards the sustainable elimination of visceral leishmaniasis in India

Delali Attip
Press releases
6 Sep 2023

Biotech leader Delali Attiogbe Attipoe joins DNDi as North America Director

Viewpoints
5 Sep 2023

Africa should bolster research into climate-sensitive diseases

Context
Prof. Sam Kariuki, DNDi Eastern Africa Director and Leonard Ithau, Rotary International District 9212 District Governor shaking hands
News
29 Aug 2023

DNDi and Rotary collaborate to prevent and treat diseases affecting neglected communities in Eastern Africa

Statements
21 Aug 2023

DNDi urges G20 to operationalize equity in response to major global health challenges and priorities

Man looking into a microscope
Press releases
31 Jul 2023

Certara and DNDi partnering to fast-track data submissions and accelerate drug approvals for neglected patients

DNDi Prof. Fahal Interview 2023 Cover Image
Videos
25 Jul 2023

Prof. Fahal On The 20 Years of Innovating Together In Helping Mycetoma Patients

Press releases
20 Jul 2023

Fiocruz signs agreement to register hepatitis C medication with Brazilian health regulatory agency

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
This website uses necessary cookies to function. If you give your consent, we will also use statistical, functional, and marketing cookies. See Cookie Policy.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo